X4 Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 3.36 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 333.13M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Ta...